Last reviewed · How we verify
GZR18
GZR18 is a long-acting basal insulin analog designed to provide sustained glucose control in diabetes.
GZR18 is a long-acting basal insulin analog designed to provide sustained glucose control in diabetes. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | GZR18 |
|---|---|
| Sponsor | Gan & Lee Pharmaceuticals. |
| Drug class | Long-acting basal insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
GZR18 is a recombinant human insulin analog engineered for extended duration of action, allowing once-daily dosing for basal insulin replacement. It is developed by Gan & Lee Pharmaceuticals, a Chinese pharmaceutical company focused on insulin and diabetes therapeutics. The drug aims to improve glycemic control while reducing injection frequency compared to conventional insulin formulations.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
Key clinical trials
- Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy (PHASE3)
- Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss (PHASE3)
- Bioequivalence Study of GZR18 Injection Before and After CMC Change (PHASE1)
- Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection (PHASE1)
- Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects (PHASE3)
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus (PHASE3)
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise (PHASE3)
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GZR18 CI brief — competitive landscape report
- GZR18 updates RSS · CI watch RSS
- Gan & Lee Pharmaceuticals. portfolio CI